Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
((Adult Respiratory Distress Syndrome OR ARDS) AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
347 results
  • Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential. [Journal Article]
    Curr Stem Cell Res Ther. 2020 Jun 01 [Online ahead of print]Xiong J, Bao L, … Shi Y
  • A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus disease 2019 (COVID-19). With the rapid increase of infected patients and deaths, it is urgent to explo…
  • Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review. [Review]
    Eur J Pediatr. 2020 May 30 [Online ahead of print]Sanna G, Serrau G, … Marcialis MA
  • CONCLUSIONS: This systematic review is aimed at summarizing all COVID-19 cases with a cardiac involvement published in paediatric age and trying to explain the underlying mechanisms responsible for COVID-19-related myocardial damage.What is Known:• Coronaviruses proved to be able to jump from animals to humans.• The outbreak of COVID-19 started from China (Dec 2019) and became pandemic.What is New:• Even in childhood, COVID-19 is not without the risk of cardiac involvement.• Myocarditis, heart failure, and arrhythmias are among the possible manifestations.
  • Neuroleptic malignant syndrome in patients with COVID-19. [Case Reports]
    Am J Emerg Med. 2020 May 22 [Online ahead of print]Soh M, Hifumi T, … Ishimatsu S
  • We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. Fentanyl, pr…
  • Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? [Journal Article]
    Dermatol Ther. 2020 May 30 [Online ahead of print]Seirafianpour F, Mozafarpoor S, … Goodarzi A
  • The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifyll…
  • Treatment algorithm for COVID-19: a multidisciplinary point of view. [Review]
    Clin Rheumatol. 2020 May 29 [Online ahead of print]Galluccio F, Ergonenc T, … Fajardo-Pérez M
  • The novel coronavirus (Sars-CoV-2) pandemic has spread rapidly, from December to the end of March, to 185 countries, and there have been over 3,000,000 cases identified and over 200,000 deaths. For a proportion of hospitalized patients, death can occur within a few days, mainly for adult respiratory distress syndrome or multi-organ dysfunction syndrome. In these patients, clinical signs and sympt…
  • Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19. [Review]
    Int J Mol Sci. 2020 May 27; 21(11)Orienti I, Gentilomi GA, Farruggia G
  • At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression t…
  • Covid-19 in Bone Marrow Transplant Recipients: Reflecting on a Single Centre Experience. [Letter]
    Br J Haematol. 2020 May 29 [Online ahead of print]Kanellopoulos A, Ahmed MZ, … Nikolousis E
  • Covid-19 disease is caused by a novel SARS-CoV-2 virus and has been declared a pandemic on the 9th of March by WHO. Hallmark of COVID-19 management is supportive care and there is still no convincing evidence on a treatment which will reduce mortality. Severe COVID-19 associated sepsis characterized by acute respiratory distress syndrome (ARDS), secondary bacterial pneumonias thrombotic complicat…
  • The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. [Review]
    Mult Scler Relat Disord. 2020 May 12; 43:102174.Baker D, Amor S, … Giovannoni G
  • CONCLUSIONS: In contrast to ablative haematopoietic stem cell therapy, most multiple-sclerosis-related disease modifying therapies do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19. In addition, few block the formation of immature B cells within lymphoid tissue that will provide antibody-mediated protection from (re)infection. However, adjustments to dosing schedules may help de-risk the chance of infection further and reduce the concerns of people with MS being treated during the COVID-19 pandemic.
  • [Obesity and risk of severe COVID-19]. [Review]
    Rev Med Suisse. 2020 May 27; 16(695):1115-1119.Scheen AJ
  • Obesity represents a higher risk of severe COVID-19 infection, which may lead to the requirement of a mechanical ventilation in intensive care units and premature death. The underlying mechanisms are multiple: alteration of the respiratory performance, presence of comorbidities such as diabetes, hypertension or obstructive sleep apnea, finally inadequate and excessive immunological responses, pos…
  • Nutrition Therapy in Critically Ill Patients with Coronavirus Disease (COVID-19). [Journal Article]
    JPEN J Parenter Enteral Nutr. 2020 May 27 [Online ahead of print]Martindale R, Patel JJ, … McClave SA
  • In the midst of a worldwide pandemic of the Coronavirus Disease 2019 (COVID-19), a paucity of data precludes derivation of COVID-19-specific recommendations for nutritional therapy. Until more data are available, the focus needs to center on principles of critical care nutrition modified for the constraints of this disease process, i.e., COVID-19-relevant recommendations. Delivery of nutritional …
  • Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. [Review]
    Br J Pharmacol. 2020 May 27 [Online ahead of print]Cleary SJ, Pitchford SC, … Page CP
  • The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 infections has led to substantial unmet need for treatments, many of which will require testing in appropriate animal models of this disease. Vaccine trials are already underway, but there remains an urgent need to find other therapeutic approaches to either target SARS-CoV-2 or the complications arising from viral infection, p…
  • COVID-19: in the footsteps of Ernest Shackleton. [Journal Article]
    Thorax. 2020 May 27 [Online ahead of print]Ing AJ, Cocks C, Green JP
  • We describe what we believe is the first instance of complete COVID-19 testing of all passengers and crew on an isolated cruise ship during the current COVID-19 pandemic. Of the 217 passengers and crew on board, 128 tested positive for COVID-19 on reverse transcription-PCR (59%). Of the COVID-19-positive patients, 19% (24) were symptomatic; 6.2% (8) required medical evacuation; 3.1% (4) were intu…
  • Intubation precautions in a pediatric patient with severe COVID-19. [Case Reports]
    J Pediatr Surg Case Rep. 2020 Jul; 58:101495.Shaw R, Tighe N, … Yuki K
  • We present the case of a child diagnosed with COVID-19 soon after open-heart surgery who required an urgent second surgery. The patient suffered from severe COVID-19 disease. The utility of preoperative COVID-19 testing, determination of recovery by an array of inflammatory markers and perioperative management are described.
  • Evaluation of fluid responsiveness during COVID-19 pandemic: what are the remaining choices? [Review]
    J Anesth. 2020 May 25 [Online ahead of print]Hasanin A, Mostafa M
  • Non-protocolized fluid administration in critically ill patients, especially those with acute respiratory distress syndrome (ARDS), is associated with poor outcomes. Therefore, fluid administration in patients with Coronavirus disease (COVID-19) should be properly guided. Choice of an index to guide fluid management during a pandemic with mass patient admissions carries an additional challenge du…
New Search Next